Stocks · News reference
Kestra Medical Technologies will report its first earnings Sept. 14, with analysts expecting a $0.62 EPS loss and $29.01M revenue.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Kestra Medical Technologies announced the appointment of Daniel Finney as Vice President of Research & Development and executive leadership team member. Finney, who has over 20 years of medical device development experience, succeeds Phillip D. Foshee, Jr. and will lead the company's innovation initiatives across the Cardiac Recovery System platform, including AI applications and strategic partnerships.
Phreesia reported Q3 2026 earnings of $0.03 per share, missing consensus estimates of $0.11 by 72.73%, though revenues slightly missed expectations at $129.46M. The stock has underperformed the S&P 500 by 41.5% year-to-date. With a Zacks Rank #3 (Hold) rating and mixed estimate revisions, the stock is expected to perform in line with the market near-term.
BTIG analyst Marie Thibault reiterates Kestra Medical Techs (NASDAQ:KMTS) with a Buy and maintains $32 price target.